BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 37474663)

  • 21. Do the existing staging systems for primary liver cancer apply to combined hepatocellular carcinoma-intrahepatic cholangiocarcinoma?
    Zhou Q; Cai H; Xu MH; Ye Y; Li XL; Shi GM; Huang C; Zhu XD; Cai JB; Zhou J; Fan J; Ji Y; Sun HC; Shen YH
    Hepatobiliary Pancreat Dis Int; 2021 Feb; 20(1):13-20. PubMed ID: 33160852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implications of ultrasound-based deep learning model for preoperatively differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Chen J; Zhang W; Bao J; Wang K; Zhao Q; Zhu Y; Chen Y
    Abdom Radiol (NY); 2024 Jan; 49(1):93-102. PubMed ID: 37999743
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined Hepatocellular-Cholangiocarcinoma: Magnetic Resonance Imaging Features and Prognosis According to Risk Factors for Hepatocellular Carcinoma.
    Kim DH; Choi SH; Kim DW; Lee SS; Lim YS; Kim SY; Kim HJ; Kim JH; Byun JH
    J Magn Reson Imaging; 2021 Jun; 53(6):1803-1812. PubMed ID: 33565208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathological characteristics of 15 patients with combined hepatocellular carcinoma and cholangiocarcinoma.
    Zuo HQ; Yan LN; Zeng Y; Yang JY; Luo HZ; Liu JW; Zhou LX
    Hepatobiliary Pancreat Dis Int; 2007 Apr; 6(2):161-5. PubMed ID: 17374575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases.
    Yano Y; Yamamoto J; Kosuge T; Sakamoto Y; Yamasaki S; Shimada K; Ojima H; Sakamoto M; Takayama T; Makuuchi M
    Jpn J Clin Oncol; 2003 Jun; 33(6):283-7. PubMed ID: 12913082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and pathological features of Allen's type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma.
    Tang D; Nagano H; Nakamura M; Wada H; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Dono K; Monden M
    J Gastrointest Surg; 2006; 10(7):987-98. PubMed ID: 16843869
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical features and outcomes of combined hepatocellular carcinoma and cholangiocarcinoma versus hepatocellular carcinoma versus cholangiocarcinoma after surgical resection: a propensity score matching analysis.
    Lin CW; Wu TC; Lin HY; Hung CM; Hsieh PM; Yeh JH; Hsiao P; Huang YL; Li YC; Wang YC; Shu CW; Chen YS
    BMC Gastroenterol; 2021 Jan; 21(1):20. PubMed ID: 33413162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Longterm prognosis of combined hepatocellular carcinoma-cholangiocarcinoma following liver transplantation and resection.
    Jung DH; Hwang S; Song GW; Ahn CS; Moon DB; Kim KH; Ha TY; Park GC; Hong SM; Kim WJ; Kang WH; Kim SH; Yu ES; Lee SG
    Liver Transpl; 2017 Mar; 23(3):330-341. PubMed ID: 28027599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk stratification of LI-RADS M and LI-RADS 4/5 combined hepatocellular cholangiocarcinoma: prognostic values of MR imaging features and clinicopathological factors.
    Wang Y; Zhu GQ; Zhou CW; Li N; Yang C; Zeng MS
    Eur Radiol; 2022 Aug; 32(8):5166-5178. PubMed ID: 35316365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Postresection Outcomes of Combined Hepatocellular Carcinoma-Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
    Yoon YI; Hwang S; Lee YJ; Kim KH; Ahn CS; Moon DB; Ha TY; Song GW; Jung DH; Lee JW; Hong SM; Yu ES; Lee SG
    J Gastrointest Surg; 2016 Feb; 20(2):411-20. PubMed ID: 26628072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathological Features and Post-resection Prognosis of Double Primary Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
    Jung DH; Hwang S; Kim KH; Hong SM; Lee YJ; Ahn CS; Moon DB; Ha TY; Song GW; Park GC; Yu ES; Lee SG
    World J Surg; 2017 Mar; 41(3):825-834. PubMed ID: 27812807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics of combined hepatocelluar-cholangiocarcinoma and comparison with intrahepatic cholangiocarcinoma.
    Kim SH; Park YN; Lim JH; Choi GH; Choi JS; Kim KS
    Eur J Surg Oncol; 2014 Aug; 40(8):976-81. PubMed ID: 24909336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radiofrequency ablation versus liver resection and liver transplantation for small combined hepatocellular-cholangiocarcinoma stratified by tumor size.
    Peng S; Dong SC; Bai DS; Zhang C; Jin SJ; Jiang GQ
    Langenbecks Arch Surg; 2023 Mar; 408(1):119. PubMed ID: 36918430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-invasive imaging in the diagnosis of combined hepatocellular carcinoma and cholangiocarcinoma.
    Shen YT; Yue WW; Xu HX
    Abdom Radiol (NY); 2023 Jun; 48(6):2019-2037. PubMed ID: 36961531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imaging features of hepatocellular carcinoma compared to intrahepatic cholangiocarcinoma and combined tumor on MRI using liver imaging and data system (LI-RADS) version 2014.
    Horvat N; Nikolovski I; Long N; Gerst S; Zheng J; Pak LM; Simpson A; Zheng J; Capanu M; Jarnagin WR; Mannelli L; Do RKG
    Abdom Radiol (NY); 2018 Jan; 43(1):169-178. PubMed ID: 28765978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of incidental/misdiagnosed intrahepatic cholangiocarcinoma and combined hepatocellular cholangiocarcinoma on the outcomes of liver transplantation: an institutional case series and literature review.
    Gupta R; Togashi J; Akamatsu N; Sakamoto Y; Kokudo N
    Surg Today; 2017 Aug; 47(8):908-917. PubMed ID: 28124125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of the Akt/mammalian target of rapamycin pathway in combined hepatocellular carcinoma and cholangiocarcinoma: significant correlation between p-4E-BP1 expression in cholangiocarcinoma component and prognosis.
    Okumura Y; Kohashi K; Tanaka Y; Kato M; Maehara Y; Ogawa Y; Oda Y
    Virchows Arch; 2020 Jun; 476(6):881-890. PubMed ID: 31927624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population.
    Chantajitr S; Wilasrusmee C; Lertsitichai P; Phromsopha N
    J Hepatobiliary Pancreat Surg; 2006; 13(6):537-42. PubMed ID: 17139428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effectiveness of transarterial chemoembolization in recurrent hepatocellular-cholangiocarcinoma after resection.
    Na SK; Choi GH; Lee HC; Shin YM; An J; Lee D; Shim JH; Kim KM; Lim YS; Chung YH; Lee YS
    PLoS One; 2018; 13(6):e0198138. PubMed ID: 29879137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiregional analysis of combined hepatocellular-cholangiocarcinoma reveals histologic diversity and molecular clonality.
    Na HY; Kim JH; Kim H; Cho JY; Han HS; Jang ES; Kim JW; Jeong SH; Heo J; Kim JW; Kim JW; Ahn S
    Histopathology; 2024 Jan; 84(2):402-408. PubMed ID: 37903726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.